Keywords: Anti-TNF agent; Crohn's disease; Loss of response; Step-up strategy; Thiopurine; Treatment de-escalation;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Whole cell-based surface plasmon resonance measurement to assess binding of anti-TNF agents to transmembrane target
Keywords: Surface plasmon resonance; Biological cell-protein interaction; Anti-TNF agent; Transmembrane TNF-α; SPR; surface plasmon resonance; TNF; tumor necrosis factor; HBSS; Hanks' balanced salt solution; EDTA; ethylenediaminetetraacetic acid; SDS; sodium dod
Original articleAlimentary tractFactors Associated With Short- and Long-Term Outcomes of Therapy for Crohn's Disease
Keywords: SONIC; Anti-TNF Agent; Tumor Necrosis Factor; Drug; ÎCRP26; change in C-reactive protein level from baseline at week 26; ATI; antibodies to infliximab; AUC; area under the curve; CD; Crohn's disease; CDEIS; Crohn's disease endoscopic index score; CI;
Original articleAlimentary tractAdalimumab for the Treatment of Japanese Patients With Intestinal Behçet's Disease
Keywords: Autoimmunity; Anti-TNF Agent; Endoscopy; Japan; AAA; anti-adalimumab antibodies; ADA; adalimumab; AE; adverse event; BD; Behçet's disease; CD; Crohn's disease; CRP; C-reactive protein; eow; every other week; GI; gastrointestinal; IBDQ; Intestinal Bow
Long-Term Outcome of Patients With Crohn's Disease Who Discontinued Infliximab Therapy Upon Clinical Remission
Keywords: Anti-Tumor Necrosis Factor; Inflammatory Bowel Disease; Anti-TNF Agent; Serology; Prognosis; VCAM; ASCA; anti-Saccharomyces cerevisiae antibodies; ATI; antibodies to infliximab; CD; Crohn's disease; CI; confidence interval; CRP; C-reactive protein;
A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab
Keywords: Anti-TNF Agent; Decision Analysis; Failed Therapy; Algorithm; ADA; adalimumab; ATI; antibodies to infliximab; CT; computed tomography; ICER; incremental cost-effectiveness ratio; IFX; infliximab; QALY; quality-adjusted life-year; TNF; tumor necrosis facto